Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd Q2 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Lincoln Pharmaceuticals Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The provided document "Q2-2025-26.pdf" does not contain any accessible content or data as it shows an error message indicating the server is temporarily unable to service the request due to the site owner reaching bandwidth limits. EBITDA: ₹2,927 Crore, a YoY increase of 10.4% - Operating Margin: 27.4%, a YoY improvement of 110 basis points (bps) - Profit After Tax (PAT): ₹1,852 Crore, a YoY growth of 16.7% - Margin Outlook: The
From Lincoln Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation does not provide any information on capex, capacity expansion, new plants, or projects.
- No amounts, status updates, or timelines are mentioned related to investments or expansions.
- The document contains only an error message about bandwidth limits and no substantive content.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹187 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key investor presentation takeaways from Morepen Laboratories Ltd's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key investor presentation takeaways from Jubilant Pharmova Ltd's Q2 FY26 investor presentation — and how it ranks against
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY26 investor presen
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY26 inve
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q2 FY26 results?
The provided document "Q2-2025-26.pdf" does not contain any accessible content or data as it shows an error message indicating the server is temporarily unable to service the request due to the site owner reaching bandwidth limits. EBITDA: ₹2,927 Crore, a YoY increase of 10.4% - Operating Margin: 27.4%, a YoY improvement of 110 basis points (bps) - Profit After Tax (PAT): ₹1,852 Crore, a YoY growth of 16.7% - Margin Outlook: The
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lincoln Pharmaceuticals Ltd planning capital expenditure?
The presentation does not provide any information on capex, capacity expansion, new plants, or projects.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.